Overview

WILEX’s lead compound is RENCAREX®* (WX-G250), a targeted antibody therapy for the treatment of solid tumours. The WX-G250 antibody was originally developed at the University of Leiden, Netherlands, by a team led by Prof. Sven Warnaar, who joined WILEX in 1999 and served as the company’s Chief Scientific Officer until he retired in June 2003.

RENCAREX® is currently in a pivotal Phase III trial as an adjuvant therapy of patients with non-metastatic renal cell cancer (RCC). In Phase I and II studies with more than 100 RCC patients completed, RENCAREX® has shown good safety and tolerability and a promising efficacy profile.

* temporary name while under development